Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer
More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation Advancement of ONA-255 marks an important milestone following Ona’s $86.6 million Series B financing Internationally recognized oncologist and physician-scientist Aleix Prat, MD, PhD, appointed Chief Medical Officer, as Jutta Amersdorffer, MD, MBA, […]
